30 Million Americans Suffer from Intestinal Ischemia

CVBT has just started work in the area of intestinal ischemia and pancreatitis, which most prominently affect elderly Americans. Based on physicians’ estimates of prevalence, we believe this application has the potential to be a significant marketplace for FGF-1141.

Cardiovascular disease in the intestinal tract can cause severe pain in people, even after the simple act of eating a meal. A new potential application for FGF-1141 is in the growing of new blood vessels in the digestive tract to address these medical conditions. Smaller blood vessels feeding the intestines or pancreas can become blocked by the same atherosclerotic process that affects the coronary arteries in the heart, resulting in restricted blood flow to the digestive tract which can lead to pain, reduced absorption of nutrients, and diminished clearance of waste.

According to a report at the 2005 Regenerative Medicine Conference, Maui, Hawaii, intestinal ischemia will affect, to some degree, almost everyone over the age of 70. Given the aging of populations throughout the western world, the number of people affected by this disease will only increase. As little can be done currently for sufferers of this disease, FGF-1141 has the potential to make a material difference for these patients.

< Back to Treatment Applications

Use of this site constitutes agreement to our Terms and Conditions
and Privacy Policy. Site Design and Contents © 2008 CardioVascular BioTherapeutics, Inc. All Rights Reserved.

Some content on this site requires the free Adobe Reader.